Transthyretin — Drug Target

All drugs that target Transthyretin — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

tafamidis · Peroxisome Proliferator Receptor alpha Agonist [EPC] · aceclofenac · Anthelmintic [EPC]

Marketed (6)

• Vyndaqel · Foldrx Pharms · tafamidis · Neuroscience
  Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils.
• Vyndaqel · Foldrx Pharms · tafamidis · Neuroscience
  Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils.
• Lopid · Pfizer · Peroxisome Proliferator Receptor alpha Agonist [EPC] · Metabolic
• Hifenac · aceclofenac · Immunology
• Vyndaqel · Foldrx Pharms · tafamidis · Neuroscience
  Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils.
• Egaten · Novartis · Anthelmintic [EPC] · Infectious Disease
  Egaten works by binding to and inhibiting the enzyme responsible for the parasite's survival.